IOL Chemicals and Pharmaceuticals Limited has released the full transcript of its business update conference call held on Friday, September 11, 2026. The company previously disclosed the availability of the audio recording on September 17, 2026, pursuant to SEBI regulations.

The disclosure was made under Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Abhay Raj Singh, Senior Vice President and Company Secretary, signed the communication on behalf of the board.

Call Details

The transcript provides detailed insights into three strategic growth initiatives involving a proposed investment of approximately ₹500 crore. Management outlined plans to expand Ibuprofen capacity by 6,000 MTPA, establish a new CDMO facility with a capacity of 1,500 million tablets per annum, and set up a dedicated specialty chemical facility under a tolling arrangement.

These initiatives are expected to contribute an incremental 25% to 30% to the top line over the coming years once fully operationalized, likely by FY29. The investments are planned to be funded through internal accruals, with around 30% of the overall funding requirements already incurred.

Key Initiatives

Management noted that the Ibuprofen expansion leverages backward integration and is expected to reach optimal utilization in FY28-FY29. The CDMO facility, which has received EU GMP certification, targets the European region and is expected to be fully operationalized in the next financial year.

Regulatory Compliance

The filing serves as a mandatory regulatory update under SEBI norms. It ensures transparency by providing market participants with direct access to management commentary from the recent investor interaction. The transcript is available on the company’s official website.

IOL Chemicals & Pharmaceuticals has announced a comprehensive expansion plan valued at approximately ₹495 crore, covering new ibuprofen capacity, a contract development and manufacturing organisation (CDMO) facility, and a dedicated specialty chemicals unit.

The initiatives, disclosed on September 9, 2026, aim to strengthen the company's manufacturing capabilities and broaden its product portfolio. All projects are proposed to be funded through internal accruals.

Ibuprofen capacity expansion

The company is setting up a fully backward-integrated manufacturing unit for ibuprofen at its existing site in Barnala, Punjab. The new facility will add 6,000 MTPA of capacity, increasing the total installed capacity from 12,000 MTPA to 18,000 MTPA upon commissioning.

The expansion addresses growing global demand for ibuprofen and leverages the company's existing customer base. Current capacity utilization stands at 95%.

New CDMO facility

IOL Chemicals has installed a pharmaceutical formulation manufacturing facility in Barnala, diversifying into Contract Development and Manufacturing Organisation (CDMO) services. The facility has an installed capacity of approximately 1,500 million tablets per annum or equivalent volume of Direct Compressible Grade.

Key details include:

• Project cost: Approximately ₹110 crore
• Target market: Anchor customers in the European region
• Regulatory status: Received GMP Certificate from Hungary's National Centre for Public Health and Pharmacy
• Expected commercialization: Q3 FY27

This initiative is designed to cater to long-term contract manufacturing requirements, leveraging the company's regulatory compliance and technical expertise.

Specialty chemicals unit

The company is establishing a dedicated manufacturing facility for a specialty chemical product under a long-term tolling arrangement with a leading global chemical company. The project involves an estimated capital expenditure of approximately ₹35 crore.

The facility will manufacture and supply the product exclusively for the customer. Commercial supplies are expected to commence during Q3 FY27. The arrangement is projected to contribute materially to the company's revenue stream.

What the Numbers Show

The total investment of ₹495 crore represents a significant commitment to capacity expansion, with the ibuprofen plant accounting for roughly 71% of the total capital outlay (₹350 crore out of ₹495 crore). This concentration underscores ibuprofen as the primary growth driver, while the smaller investments in CDMO and specialty chemicals signal a strategic push into higher-value, service-oriented segments to diversify revenue streams beyond pure API manufacturing.